Prescription pattern of antipsychotic drugs for schizophrenic inpatients in Japan: Research on East Asia Psychotropic Prescription Pattern-Antipsychotics study [5]

Psychiatry and Clinical Neurosciences

Volumn 60, Issue 6, 2006, Pages 778-779

  Yoshimura, Reiji ^a,l   Okamoto, Tatsuya ^a   Nakamura, Jun ^a   Tateno, Masaru ^b   Otsuka, Kotaro ^c   Takahashi, Hidehiko ^d   Fujisawa, Daisuke ^e   Takamatsu, Toko ^f   Fujii, Senta ^g   Sato, Soichiro ^h   Inoue, Masayuki ⁱ   Sasaki, Hiromitsu ⁱ   Kuroki, Toshihide ^j   Shinfuku, Naotaka ^k  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

^c IWATE MEDICAL UNIVERSITY   (Japan)

^d Asai Hospital   (Japan)

^e Sakuragaoka Memorial Hospital   (Japan)

^f KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g Hyogo Institute for Traumatic Stress   (Japan)

^h Jikei Institute of Psychiatry   (Japan)

ⁱ Fukuma Hospital   (Japan)

^j KYUSHU UNIVERSITY   (Japan)

^k SEINAN GAKUIN UNIVERSITY   (Japan)

^l NONE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PEROSPIRONE; QUETIAPINE; RISPERIDONE; SULPIRIDE; ZOTEPINE;

AGGRESSION; CATATONIA; DELUSION; HALLUCINATION; HUMAN; INFORMATION PROCESSING; JAPAN; LETTER; NEGATIVE SYNDROME; PATIENT COMPLIANCE; PATIENT SELECTION; PRESCRIPTION; SCHIZOPHRENIA; SOCIAL DISABILITY; SPEECH DISORDER; STANDARDIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; DRUG UTILIZATION; FEMALE; HUMANS; INPATIENTS; JAPAN; MALE; MIDDLE AGED; PRESCRIPTIONS, DRUG; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA;

EID: 33750953436     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2006.01601.x     Document Type: Letter

References (9)

1. Chong M-Y, Tan CH, Fujii S et al. Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry Clin. Neurosci. 2004; 58: 61-67.
2. Inagaki A, Inada T, Fujii Y et al. Equivalent Dose of Psychotropics. Seiwa Shoten, Tokyo, 1999.
3. Inagaki A, Inada T, Fujii Y et al. Dose equivalence of psychotropic drugs. Part XV: dose equivalence of novel neuroleptics. Perospirone. Jpn J. Clin. Psychopharmacol. 2001; 4: 869-870.
4. Bezchlibnyk-Butler KZ, Jeffries JJ. Clinical Handbook of Psychotropic Drugs, 11th edn. Hogrefe and Huber, Toronto, 2001.
5. Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J. Clin. Psychiatry 2001; 62: 153-157.
6. Yoshimura R, Nakamura J, Shinkai K et al. An open study of risperidone liquid in the acute phase of schizophrenia. Hum. Psychopharmacol. 2005; 20: 243-248.
7. Citrome L. Use of lithium, carbamazepine, and valproic acid in a state-operated psychiatric hospital. J. Pharm. Tech. 1995; 11: 55-59.
8. McEvoy JP, Scheifler PL, Frances A. The expert consensus guideline series: treatment of schizophrenia. J. Clin. Psychiatry 1999; 60 (Suppl.): 815-818.
9. Biancosino B, Barbui C, Marmai L, Dona S, Grassi L. Determination of antipsychotic polypharmacy in psychiatric inpatients: a prospective study. Int. Clin. Psychopharmacol. 2005; 20: 305-309.